Aadi Biosciences Inc

AADI | $1.95 2.63% 7.2K

(0.0% 1d) (-12.4% 1m) (-76.0% 1y) (0.0% 2d) (0.0% 3d) (3.3% 7d) (27.03% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 47,880,700
https://www.aerpio.com
Sec Filling | Patents | 12 employees

(US) Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 for indications in which the Company believes that activation of Tie2 may have therapeutic potential. The Company's lead compound, razuprotafib (formerly AKB-9778), a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase ("VE-PTP"). The Company is also evaluating development options for ARP-1536, a humanized monoclonal antibody, for its therapeutic potential in the treatment of diabetic vascular complications including nephropathy and diabetic macular edema ("DME"). The Company's third asset is a bispecific antibody that binds both VEGF and VE-PTP which is designed to inhibit VEGF activation and activate Tie2. This bispecific antibody has the potential to be an improved treatment for wet age-related macular degeneration and DME via intravitreal injection. Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class small molecule inhibitor of hypoxia-inducible factor-1 (HIF). GB004 is being developed by AKB-4924's exclusive licensor, Gossamer Bio, Inc.. In January 2021, the Company announced that it had initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company's clinical assets and cash resources.

monoclonal antibodies antibody treatment diabetic diabetes injection macular

add to watch list Paper trade email alert is off

Press-releases

Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)
Published: 2024-03-17 (Crawled : 12:20) - prnewswire.com
AADI | $1.95 2.63% 7.2K

Manufacturing

| Email alert Add to watchlist
origin bioscience advanced

Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
Published: 2024-03-13 (Crawled : 14:30) - biospace.com/
AADI | $1.95 2.63% 7.2K

Manufacturing

| -2.06% | O: 0.0% H: 0.0% C: 0.0%
bioscience update financial results

Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update
Published: 2024-03-06 (Crawled : 17:00) - biospace.com/
AADI | $1.95 2.63% 7.2K

Manufacturing

| -9.95% | O: 0.47% H: 4.72% C: 2.83%
report bioscience update results

Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa
Published: 2024-03-01 (Crawled : 22:00) - biospace.com/
AADI | $1.95 2.63% 7.2K

Manufacturing

| -3.55% | O: 1.02% H: 0.0% C: 0.0%
fyarro bioscience publication treatment

Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference
Published: 2024-02-26 (Crawled : 21:00) - prnewswire.com
AADI | $1.95 2.63% 7.2K

Manufacturing

| -4.04% | O: 0.51% H: 7.53% C: 4.02%
conference bioscience

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium
Published: 2024-01-26 (Crawled : 22:00) - prnewswire.com
AADI | $1.95 2.63% 7.2K

Manufacturing

| Email alert Add to watchlist
symposium bioscience

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium
Published: 2024-01-19 (Crawled : 22:00) - prnewswire.com
AADI | $1.95 2.63% 7.2K

Manufacturing

| Email alert Add to watchlist
symposium bioscience gastrointestinal

Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations
Published: 2023-12-14 (Crawled : 21:00) - prnewswire.com
AADI | $1.95 2.63% 7.2K

Manufacturing

| -64.62% | O: -56.42% H: 15.81% C: 0.0%
tumors bioscience trial results

Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update
Published: 2023-11-08 (Crawled : 14:00) - biospace.com/
AADI | $1.95 2.63% 7.2K

Manufacturing

| -60.58% | O: -1.24% H: 0.0% C: -2.31%
bioscience update financial results

Aadi Bioscience to Participate in Jefferies London Healthcare Conference
Published: 2023-11-06 (Crawled : 21:00) - prnewswire.com
AADI | $1.95 2.63% 7.2K

Manufacturing

| -60.82% | O: -0.82% H: 1.04% C: 0.21%
conference bioscience

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001415889-24-006421	4	2024-03-05	2024-03-04	Sell	S	14964	1411543
0001415889-24-006421	4	2024-03-05	2024-03-01	Sell	S	27036	1426507
0001415889-24-006416	4	2024-03-05	2024-03-01	Buy	A	30000	30000
0001415889-24-006416	4	2024-03-05	2024-03-01	Buy	A	60000	60000
0001415889-24-006416	4	2024-03-05	2024-03-01	Buy	A	76813	76813
0001209191-24-000254	4	2024-01-03	2024-01-02	Sell	S	42000	1495543
0001209191-23-057545	4	2023-12-05	2023-12-05	Sell	S	15740	1544580
0001209191-23-057545	4	2023-12-05	2023-12-04	Sell	S	10876	1560320
0001209191-23-057545	4	2023-12-05	2023-12-01	Sell	S	8347	1571196